AR086051A1 - Metodo para tratar el cancer colorrectal, composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecano (folfiri), articulo manufacturado, kit - Google Patents
Metodo para tratar el cancer colorrectal, composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecano (folfiri), articulo manufacturado, kitInfo
- Publication number
- AR086051A1 AR086051A1 ARP120101420A ARP120101420A AR086051A1 AR 086051 A1 AR086051 A1 AR 086051A1 AR P120101420 A ARP120101420 A AR P120101420A AR P120101420 A ARP120101420 A AR P120101420A AR 086051 A1 AR086051 A1 AR 086051A1
- Authority
- AR
- Argentina
- Prior art keywords
- folinic acid
- aflibercept
- composition
- irinotecano
- folfiri
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/178—Lectin superfamily, e.g. selectins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composición farmacéutica que comprende aflibercept, ácido folínico, 5-fluorouracilo (5-FU) e irinotecano (FOLFIRI) útil para el tratamiento del cáncer colorrectal (CRC).Reivindicación 1: Un método para tratar el cáncer colorrectal (CRC) o un síntoma del cáncer colorrectal (CRC) en un paciente que lo necesite, comprendiendo dicho método administrar a dicho paciente cantidades terapéuticamente eficaces de aflibercept, ácido folínico, 5-fluorouracilo (5-FU) e irinotecano. Reivindicación 24: Una composición que comprende cantidades terapéuticamente eficaces de aflibercept en combinación con ácido folínico, 5-fluorouracilo (5-FU) e irinotecano para tratar pacientes con CRC, en la que las administraciones de aflibercept, ácido folínico, 5-fluorouracilo (5-FU) e irinotecano se espacian a lo largo de un periodo de tiempo para obtener la máxima eficacia de la combinación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11305490 | 2011-04-26 | ||
EP11306154 | 2011-09-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR086051A1 true AR086051A1 (es) | 2013-11-13 |
Family
ID=46001286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120101420A AR086051A1 (es) | 2011-04-26 | 2012-04-25 | Metodo para tratar el cancer colorrectal, composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecano (folfiri), articulo manufacturado, kit |
Country Status (38)
Country | Link |
---|---|
US (1) | US11033606B2 (es) |
EP (2) | EP3210617A1 (es) |
JP (1) | JP6114257B2 (es) |
KR (2) | KR20190088568A (es) |
CN (1) | CN103608029A (es) |
AR (1) | AR086051A1 (es) |
AU (1) | AU2012247530B2 (es) |
BR (1) | BR112013027356A2 (es) |
CA (1) | CA2833592A1 (es) |
CL (1) | CL2013003082A1 (es) |
CO (1) | CO6811861A2 (es) |
CR (1) | CR20130547A (es) |
CY (1) | CY1120382T1 (es) |
DK (1) | DK2701724T3 (es) |
DO (1) | DOP2013000248A (es) |
EA (1) | EA025182B1 (es) |
EC (1) | ECSP13013044A (es) |
ES (1) | ES2637074T3 (es) |
GT (1) | GT201300260A (es) |
HR (1) | HRP20171216T1 (es) |
HU (1) | HUE034288T2 (es) |
IL (2) | IL228947B (es) |
JO (1) | JO3283B1 (es) |
LT (1) | LT2701724T (es) |
MA (1) | MA35130B1 (es) |
MX (1) | MX341348B (es) |
NI (1) | NI201300112A (es) |
PE (2) | PE20171516A1 (es) |
PL (1) | PL2701724T3 (es) |
PT (1) | PT2701724T (es) |
RS (1) | RS56177B1 (es) |
SG (2) | SG194613A1 (es) |
SI (1) | SI2701724T1 (es) |
TW (1) | TWI599369B (es) |
UA (1) | UA114708C2 (es) |
UY (1) | UY34036A (es) |
WO (1) | WO2012146610A1 (es) |
ZA (1) | ZA201308821B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
CN104853763A (zh) * | 2012-08-02 | 2015-08-19 | 赛诺菲 | 包含阿柏西普或ziv-阿柏西普的制品 |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
LT3170005T (lt) * | 2014-07-18 | 2019-07-10 | Sanofi | Paciento, įtariamo, kad serga vėžiu, gydymo afliberceptu rezultato prognozavimo būdas |
JP6692358B2 (ja) * | 2014-09-16 | 2020-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 転移性結腸直腸癌の抗血管新生療法に関連する予測的及び予後的バイオマーカー |
US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
SI3337467T1 (sl) | 2015-08-20 | 2021-03-31 | Ipsen Biopharm Ltd. Ash Road | Kombinacijska terapija, ki vsebuje liposomski irinotekan in zaviralec PARP za zdravljenje raka |
TW202126293A (zh) | 2015-08-21 | 2021-07-16 | 英商益普生生物製藥有限公司 | 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法 |
KR101936049B1 (ko) * | 2015-10-15 | 2019-01-08 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 생산방법 |
JP7088454B2 (ja) | 2015-12-30 | 2022-06-21 | コディアック サイエンシーズ インコーポレイテッド | 抗体および抗体複合体 |
MX2018009112A (es) * | 2016-01-25 | 2018-08-28 | Sanofi Sa | Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer mediante la medicion del nivel de un biomarcador plasmatico. |
WO2018083470A1 (en) | 2016-11-02 | 2018-05-11 | Ipsen Biopharm Ltd. | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
JOP20200275A1 (ar) | 2018-05-10 | 2020-11-02 | Regeneron Pharma | صيغ تحتوي على بروتين اندماج لمستقبلvegf مرتفعة التركيز |
JP2021526161A (ja) * | 2018-05-30 | 2021-09-30 | マショーヴァー, デイビィッドMACHOVER, David | 癌治療のための方法及び医薬組成物 |
WO2021050094A1 (en) * | 2019-09-11 | 2021-03-18 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6019790B2 (ja) | 1977-11-18 | 1985-05-17 | 株式会社日立製作所 | 光硬化型接着性組成物とそれを用いて被着体を接着する方法 |
US4353887A (en) | 1979-08-16 | 1982-10-12 | Ciba-Geigy Corporation | Divisible tablet having controlled and delayed release of the active substance |
JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
WO1993000807A1 (en) | 1991-07-03 | 1993-01-21 | Cryolife, Inc. | Method for stabilization of biomaterials |
US5474796A (en) | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
AU670793B2 (en) | 1992-04-30 | 1996-08-01 | Alpha Therapeutic Corporation | Improved solubilization and stabilization of factor VIII complex |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
ES2230542T3 (es) | 1993-03-25 | 2005-05-01 | MERCK & CO., INC. | Inhibidor del factor de crecimiento celular endotelial vascular. |
US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
US6040157A (en) | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
GB9410533D0 (en) | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | In situ hybridisation and immuno-Chemical localisation of a growth factor |
GB9410534D0 (en) | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | Improvements in or relating to growth factor inhibitors |
TW438775B (en) | 1995-04-07 | 2001-06-07 | Pharmacia & Upjohn Co Llc | Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
JPH09154588A (ja) | 1995-10-07 | 1997-06-17 | Toagosei Co Ltd | Vegf結合性ポリペプチド |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
DE69736860T2 (de) | 1996-09-24 | 2007-05-16 | Merck & Co., Inc. | Verbindungen zur hemmung der angiogenese durch gentherapie |
US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
DE19724793A1 (de) | 1997-06-06 | 1998-12-10 | Schering Ag | D-mutierte Peptide mit VEGF-Rezeptor blockierenden Eigenschaften |
US6075007A (en) | 1997-07-17 | 2000-06-13 | Regeneron Pharmaceuticals, Inc. | Modified noggin polypeptide and compositions |
JPH1180024A (ja) | 1997-09-12 | 1999-03-23 | Toagosei Co Ltd | 角膜血管新生阻害剤 |
US6436897B2 (en) | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
DE19841985A1 (de) | 1998-09-03 | 2000-03-09 | Schering Ag | Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate |
US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
WO2000034337A1 (en) | 1998-12-10 | 2000-06-15 | Tsukuba Research Laboratory, Toagosei Co., Ltd. | Humanized monoclonal antibodies against vascular endothelial cell growth factor |
AP1243A (en) | 1999-02-01 | 2004-02-02 | Servier Lab | Core tablet for controlled release of gliclazide after oral administration. |
ES2223705T3 (es) | 1999-04-28 | 2005-03-01 | Board Of Regents, The University Of Texas System | Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf. |
WO2000066125A1 (en) | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
US7303746B2 (en) | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
US6833349B2 (en) | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
CN101433715B (zh) | 1999-06-08 | 2013-04-17 | 里珍纳龙药品有限公司 | 具有改善的药物动力学特性的修饰嵌合多肽 |
US7001892B1 (en) | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
DE19938724A1 (de) | 1999-08-16 | 2001-02-22 | Tetra Laval Holdings & Finance | Vorrichtung zur Herstellung von Kunststoffbehältern mittels Streckblasformen |
GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
US6500633B1 (en) | 2000-04-26 | 2002-12-31 | Atairgin Technologies, Inc. | Method of detecting carcinomas |
AR028424A1 (es) | 2000-05-10 | 2003-05-07 | Bayer Corp | Metodo para regular la angiogenesis utilizando proteina ryk |
PT1324776E (pt) | 2000-10-12 | 2009-12-23 | Genentech Inc | Formulações de proteína concentradas de viscosidade reduzida |
US20030092019A1 (en) | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
US20040023864A1 (en) | 2001-05-09 | 2004-02-05 | Steve Roczniak | Method of regulating angiogenesis using ryk protein |
JP4317010B2 (ja) | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ,インコーポレイティド | IgG抗体の安定な凍結乾燥医薬製剤 |
NZ534999A (en) | 2002-03-01 | 2007-03-30 | Pharmacia Italia Spa | Crystalline polymorphic form c of irinotecan hydrochloride |
JP2004006671A (ja) | 2002-03-22 | 2004-01-08 | Sanyo Electric Co Ltd | 電荷結合素子およびその製造方法 |
US7052691B2 (en) | 2003-03-28 | 2006-05-30 | Regeneron Pharmaceuticals, Inc. | Methods of treating diabetes by blocking VEGF-mediated activity |
ZA200507757B (en) | 2003-04-04 | 2007-01-31 | Genentech Inc | High concentration antibody and protein formulations |
US7300654B2 (en) | 2003-05-28 | 2007-11-27 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection in high risk keratoplasty patients |
CA2519835A1 (en) | 2003-05-28 | 2004-12-09 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection |
US7186699B2 (en) | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
US7354578B2 (en) | 2003-06-06 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Method of tumor regression with VEGF inhibitors |
US7399612B2 (en) | 2003-06-30 | 2008-07-15 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
US20050196340A1 (en) | 2003-08-06 | 2005-09-08 | Jocelyn Holash | Use of a VEGF antagonist in combination with radiation therapy |
JP2007501239A (ja) | 2003-08-06 | 2007-01-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 放射線治療と組み合わせたvegfアンタゴニストの使用 |
AU2003257853A1 (en) | 2003-08-14 | 2005-03-07 | Fujitsu Limited | Computer device and cluster server device |
KR101471732B1 (ko) | 2003-08-27 | 2014-12-16 | 옵쏘테크 코포레이션 | 안구의 혈관신생성 장애를 치료하기 위한 조합 치료법 |
EP1529620B1 (fr) | 2003-11-06 | 2009-02-25 | Nestlé Waters Management & Technology | Procédé de fabrication de contenants en résine polyester |
WO2005046602A2 (en) | 2003-11-10 | 2005-05-26 | Greenville Hospital System | Vegf receptor antagonists |
WO2005072772A1 (en) | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
WO2005123104A2 (en) | 2004-06-10 | 2005-12-29 | Regeneron Pharmaceuticals, Inc. | Use of vegf inhibitors for the treatment of human cancer |
JP2008503481A (ja) | 2004-06-18 | 2008-02-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 悪性胸膜滲出液の処置のためのvegfインヒビターの投与および使用の方法 |
CA2567795C (en) | 2004-07-30 | 2013-06-11 | Regeneron Pharmaceuticals, Inc. | Methods of treating type i diabetes by blocking vegf-mediated activity |
NZ590132A (en) | 2004-10-21 | 2012-03-30 | Genentech Inc | Dosage regime for treating intraocular neovascular diseases with VEGF |
FR2878749B1 (fr) | 2004-12-03 | 2007-12-21 | Aventis Pharma Sa | Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives |
WO2006088650A2 (en) | 2005-02-02 | 2006-08-24 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a vegf inhibitor |
EP1853298A2 (en) | 2005-02-11 | 2007-11-14 | Regeneron Pharmaceuticals, Inc. | Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent |
EP1855708A1 (en) | 2005-03-11 | 2007-11-21 | Regeneron Pharmaceuticals, Inc. | Treating anemia by inhibition of vegf |
NZ560713A (en) | 2005-03-25 | 2010-11-26 | Regeneron Pharma | VEGF antagonist formulations |
MX2008001966A (es) | 2005-08-12 | 2008-03-26 | Regeneron Pharma | Tratamiento de enfermedades mediante administracion subcutanea de un antagonista vegf. |
US7354582B2 (en) | 2006-03-10 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Use of VEGF antagonists for the treatment of malignant gliomas |
KR101406811B1 (ko) | 2006-06-16 | 2014-06-12 | 리제너론 파마슈티칼스 인코포레이티드 | 유리체내 투여에 적당한 vegf 길항제 제형 |
RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
US20100216168A1 (en) | 2007-03-23 | 2010-08-26 | Precision Therapeutics, Inc. | Methods for evaluating angiogenic potential in culture |
FR2918279B1 (fr) | 2007-07-05 | 2010-10-22 | Aventis Pharma Sa | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
CN100546578C (zh) * | 2007-08-10 | 2009-10-07 | 河北医科大学 | 一种抗癌药物组合物及其在制备抗癌药物中的应用 |
HUE029665T2 (en) | 2007-10-04 | 2017-03-28 | Onyx Therapeutics Inc | Synthesis of crystalline peptide epoxy ketone protease inhibitors and amino acid keto epoxides \ t |
EP2220492B1 (en) | 2007-11-30 | 2011-08-31 | Genentech, Inc. | Vegf polymorphisms and anti-angiogenesis therapy |
EP2143542A1 (fr) | 2008-07-07 | 2010-01-13 | Nestec S.A. | Procédé et dispositif de conditionnement d'un liquide alimentaire |
FR2933702A1 (fr) | 2008-07-08 | 2010-01-15 | Sanofi Aventis | Antagonistes specifiques du recepteur fgf-r4 |
WO2010022201A2 (en) | 2008-08-22 | 2010-02-25 | Osteogenex Inc. | Folinic acid derivatives for promoting bone growth |
EP2347256A4 (en) | 2008-10-09 | 2012-02-08 | Alfagene Bioscience Inc | USE AND IDENTIFICATION OF BIOMARKERS FOR GASTROINTESTINAL DISEASES |
US20120003641A1 (en) | 2008-11-05 | 2012-01-05 | Graham Robert R | Genetic polymorphisms in age-related macular degeneration |
EP2413965A1 (en) | 2009-03-31 | 2012-02-08 | Roche Glycart AG | Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan |
WO2010124264A2 (en) | 2009-04-24 | 2010-10-28 | University Of Southern California | Genetic variants in angiogenesis pathway associated with clinical outcome |
EP2459456B1 (en) | 2009-07-31 | 2018-04-25 | Amcor Group GmbH | Hot-fill container |
US8221753B2 (en) * | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
EP2678441B1 (en) | 2011-02-23 | 2017-10-18 | Sanofi | Single nucleotide polymorphisms in the promoter of vegfa gene and their use as predictive markers for anti-vegf treatments |
JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
JP6019790B2 (ja) | 2012-06-19 | 2016-11-02 | 富士電機株式会社 | 接合方法及び接合部材 |
CN104853763A (zh) | 2012-08-02 | 2015-08-19 | 赛诺菲 | 包含阿柏西普或ziv-阿柏西普的制品 |
LT3170005T (lt) | 2014-07-18 | 2019-07-10 | Sanofi | Paciento, įtariamo, kad serga vėžiu, gydymo afliberceptu rezultato prognozavimo būdas |
MX2018009112A (es) | 2016-01-25 | 2018-08-28 | Sanofi Sa | Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer mediante la medicion del nivel de un biomarcador plasmatico. |
-
2012
- 2012-04-24 JO JOP/2012/0097A patent/JO3283B1/ar active
- 2012-04-25 MX MX2013012387A patent/MX341348B/es active IP Right Grant
- 2012-04-25 KR KR1020197020546A patent/KR20190088568A/ko not_active Application Discontinuation
- 2012-04-25 AR ARP120101420A patent/AR086051A1/es unknown
- 2012-04-25 SI SI201231040T patent/SI2701724T1/sl unknown
- 2012-04-25 JP JP2014506843A patent/JP6114257B2/ja active Active
- 2012-04-25 PT PT127171296T patent/PT2701724T/pt unknown
- 2012-04-25 EP EP17157891.7A patent/EP3210617A1/en not_active Withdrawn
- 2012-04-25 PE PE2017001505A patent/PE20171516A1/es unknown
- 2012-04-25 HU HUE12717129A patent/HUE034288T2/en unknown
- 2012-04-25 SG SG2013079058A patent/SG194613A1/en unknown
- 2012-04-25 RS RS20170801A patent/RS56177B1/sr unknown
- 2012-04-25 CA CA2833592A patent/CA2833592A1/en active Pending
- 2012-04-25 KR KR1020137030891A patent/KR102002653B1/ko active IP Right Grant
- 2012-04-25 ES ES12717129.6T patent/ES2637074T3/es active Active
- 2012-04-25 WO PCT/EP2012/057542 patent/WO2012146610A1/en active Application Filing
- 2012-04-25 SG SG10201610829UA patent/SG10201610829UA/en unknown
- 2012-04-25 PL PL12717129T patent/PL2701724T3/pl unknown
- 2012-04-25 BR BR112013027356A patent/BR112013027356A2/pt not_active Application Discontinuation
- 2012-04-25 CN CN201280031198.9A patent/CN103608029A/zh active Pending
- 2012-04-25 EP EP12717129.6A patent/EP2701724B1/en active Active
- 2012-04-25 US US14/113,757 patent/US11033606B2/en active Active
- 2012-04-25 DK DK12717129.6T patent/DK2701724T3/en active
- 2012-04-25 UA UAA201313713A patent/UA114708C2/uk unknown
- 2012-04-25 LT LTEP12717129.6T patent/LT2701724T/lt unknown
- 2012-04-25 PE PE2013002411A patent/PE20140616A1/es not_active Application Discontinuation
- 2012-04-25 AU AU2012247530A patent/AU2012247530B2/en active Active
- 2012-04-25 EA EA201391577A patent/EA025182B1/ru not_active IP Right Cessation
- 2012-04-26 TW TW101115009A patent/TWI599369B/zh active
- 2012-04-26 UY UY0001034036A patent/UY34036A/es not_active Application Discontinuation
-
2013
- 2013-10-17 IL IL228947A patent/IL228947B/en active IP Right Grant
- 2013-10-18 NI NI201300112A patent/NI201300112A/es unknown
- 2013-10-22 DO DO2013000248A patent/DOP2013000248A/es unknown
- 2013-10-23 GT GT201300260A patent/GT201300260A/es unknown
- 2013-10-24 CL CL2013003082A patent/CL2013003082A1/es unknown
- 2013-10-24 CR CR20130547A patent/CR20130547A/es unknown
- 2013-11-20 MA MA36457A patent/MA35130B1/fr unknown
- 2013-11-22 ZA ZA2013/08821A patent/ZA201308821B/en unknown
- 2013-11-25 EC ECSP13013044 patent/ECSP13013044A/es unknown
- 2013-11-26 CO CO13277422A patent/CO6811861A2/es unknown
-
2017
- 2017-08-08 HR HRP20171216TT patent/HRP20171216T1/hr unknown
- 2017-08-22 CY CY20171100890T patent/CY1120382T1/el unknown
-
2018
- 2018-01-28 IL IL257179A patent/IL257179A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR086051A1 (es) | Metodo para tratar el cancer colorrectal, composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecano (folfiri), articulo manufacturado, kit | |
MX2021004821A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
MX2021000609A (es) | Métodos de tratamiento con fármacos sustrato para cyp3a4. | |
EA201800199A1 (ru) | Применение akkermansia muciniphila для лечения метаболических расстройств, увеличения расхода энергии и снижения веса, композиции, лекарственное стедство | |
EA201491584A1 (ru) | Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor | |
MX2016005532A (es) | Metodos para usar oxido nitrico en un estado de plasma para tratar condiciones medicas y enfermedades. | |
MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
RU2018135973A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака | |
PH12017501300A1 (en) | Novel iodophor composition and methods of use | |
PH12017500392A1 (en) | Medical treatments based on anamorelin | |
MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
NZ726132A (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
PH12018501769A1 (en) | Medicament for treatment of diabetic foot infections | |
EA201491629A1 (ru) | Способы лечения рака с использованием липоплатина | |
UA97663U (uk) | Спосіб лікування вертеброгенного больового корінцевого синдрому у хворих на розсіяний склероз | |
RU2012158011A (ru) | Метод и композиция для лечения рака | |
PL408261A1 (pl) | Plaster zawierający substancje przeciwbólowe jako innowacyjna forma aplikacji , łagodzenia oraz leczenia bólu | |
MX2011011881A (es) | Uso de la delfinidina y sus derivados para preparar un medicamento para el tratamiento de la prediabetes y diabetes. | |
RU2010116989A (ru) | Способ лечения саркоидоза кожи | |
PL408262A1 (pl) | Plaster zawierający substancje przeciwobrzękowe jako innowacyjna forma aplikacji w leczeniu stłuczeń oraz kontuzji narządu ruchu | |
RU2010147965A (ru) | Способ лечения флегмон тыльной поверхности кисти у детей |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |